Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Syntactx | NETWORK |
Not provided
Not provided
Not provided
Not provided
The ASOLO-SCI investigation is a Post Market Clinical Follow-up (PMCF) study to investigate the safety and performance of the Avance® Solo NPWT System in treating low to moderate exuding surgically closed incisions for up to 14 days when used in accordance with the Instructions for Use (IfU).
The ASOLO-SCI investigation is designed as a prospective, open, non-comparative, PMCF study to investigate the safety and performance of the Avance® Solo NPWT System in treating low to moderate exuding surgically closed incisions for up to 14 days when used in accordance with the IfU in up to 34 patients (n=34).
The ASOLO-SCI investigation is a multicentre study that is expected to take place in approximately three European centres.
The study treatment shall be stopped earlier (i.e. prior to 14 days), in the event study Subjects withdraw their consent, or shall the Principal Investigator and clinical team deem the Avance® Solo NPWT System to be no longer adequate for the study Subject's wound. Following termination of Subject participation for whichever reason in the study, the patient shall be followed in accordance with the local standard of care in wound management and treatment.
As a primary endpoint, the Principal Investigator and clinical team will evaluate whether the surgical incision remains closed, from baseline to study end at Day 14.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects with a low to moderate exuding surgically closed incision | Experimental | Up to 34 study Subjects with a low to moderate exuding surgically closed incision deemed adequate by the Principal Investigator and clinical team for NPWT treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avance® Solo NPWT System | Device | Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in wound remaining closed | The evaluation of the wound remaining closed is captured through an assessment by the Principal Investigator/clinical team from baseline to the final visit (wound remaining closed yes/no). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Wound progress to baseline | Wound progress in low to moderate surgically closed incisions compared between baseline and final visit (deteriorated/no change/improved). | Day 14 (+0/-2 days) |
| Change in wound progress across visits |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre Welikow, MD | Contact | 0046317223045 | alexandre.welikow@molnlycke.com | |
| Tahmina Haider, MSc | Contact | 0046739503674 | tahmina.haider@molnlycke.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000072836 | Surgical Wound |
| D013529 | Surgical Wound Dehiscence |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Single group of Subjects (with a low to moderate exuding surgically closed incision) in use of the Avance® Solo NPWT System.
Not provided
Not provided
Not provided
Not provided
Wound progress in low to moderate surgically closed incisions compared to last visit (deteriorated/no change/improved).
| Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Change in lack of dermal opposition | Lack of dermal opposition as a percentage of the total wound length from baseline to all follow-up visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Change in exudate amount | Change in exudate amount from baseline to all follow-up visits (none/low/moderate/high). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Change in exudate nature | Change in exudate nature from baseline to all follow-up visits (serous/fibrinous/serosanguinous/sanguineous/seropurulent/purulent/foul purulent//haemopurulent/haemorrhagic). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Change in exudate odour | Change in exudate odour from baseline to all follow-up visits (no odour/slight/moderate/strong/very strong). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Change in peri-wound conditions | Change in peri-wound skin condition from baseline to all follow-up visits (normal/erythematous/oedematous/eczematous/excoriated/macerated/indurated). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Pain assessment | Subject evaluation of pain at Avance® Solo Border Dressing and Avance® Solo Fixation Strips removal using a Numeric Rating Scale at each follow-up visit (where the Subject verbally grade their pain on a level from 0 to 10, where 0 indicates no pain and 10 the worst imaginable for the Subject; the NRS will be used before and during dressing removal). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Absorption and transportation of exudate | Clinical assessment of Avance® Solo NPWT System's ability to absorb and/or transport exudate using a rating scale at all follow-up visits (very poor/poor/good/very good). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Trauma to the wound's surrounding skin | Proportion of Subjects with trauma (e.g. blistering) to the wound site and surrounding skin for Avance® Solo Border Dressing and Avance® Solo Fixation Strips at all follow-up visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| System wear time | Evaluate system wear time in days from baseline to all follow-up visits including potential extra visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Sounding of alarms | Subject evaluation of the system properties (number of sounding alarms) assessed at all follow-up visits (souding of alarms in the following intervals 0, 1-5, 6-10, 11-15, 16-20, more than 20). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Product consumption | Product consumption of the utilised products for the system, from baseline to final visit using the Avance® Solo NPWT System (in total number of Avance® Solo Pumps, Border Dressing, Canisters, Fixation Strips, and batteries). | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Subject quality of life assessment | Subject evaluation of the Avance® Solo NPWT system impact of everyday life at day 14 or final visit. Quality of life is assessed using Numeric Rating Scale (NRS) where the Subject grades how much the treatment has affected their daily life. 0 is equal to no influence, and 10 is equal to considerable influence on everyday life or unbearable. If replying >0, the Subject shall state the presence or absence of the following causes: leakage of dressing, impaired mobility, difficulties in getting dressed, pain, and odour. | Day 14 (+0/-2 days) |
| Ease of application and removal of the Avance® Solo NPWT System | Clinician evaluation of ease of application and removal of the Avance® Solo NPWT System using a Numeric Rating Scale collected at baseline and each follow-up visit (from 0 to 10, wherein 0 is equal to no problem with application or removal, and 10 is the worst imaginable situation when applying/removing the system from a Subject). | Baseline, Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Subject compliance | Evaluate the Subject compliance to Avance® Solo NPWT System therapy at all follow-up visits by the average number of hours per day that the system has not provided NPWT since the Subject's last visit. | Day 7 (+0/-2 days), Day 14 (+0/-2 days) |
| Global satisfaction | Evaluation of the Principal Investigator and Subject's global satisfactions with the system at day 14 or final visit (very dissatisfied/dissatisfied/neither dissatisfied or satisfied/satisfied/very satisfied). | Day 14 (+0/-2 days) |